leisure time -WSS

leisure time

author：knowledge 2025-10-04 08:06:07 - browse：28

An illustrated portrait of Eli Lilly's David Ricks and Skovronsky – biotech and pharma coverage from STAT — Eli Lilly CEO David Ricks (left) and Chief Scientific Officer Daniel S. Skovronsky Molly Ferguson for STAT

The partnership that would shape Eli Lilly into one of the biggest success stories in the pharmaceutical industry began with conversations around a relatively minor acquisition.

At the time, David Ricks was running Lilly’s U.S. business and was part of the team charged with evaluating Avid Radiopharmaceuticals, which Lilly would go on to purchase in 2010 for a paltry $300 million — couch change for a multibillion-dollar firm. But what struck Ricks was not the company’s technology, for imaging Alzheimer’s plaques, but Avid’s CEO, Daniel S. Skovronsky.

“Dan’s different,” Ricks told STAT. “I had this sense immediately. Some people get in biotech for the cha-ching.” Skovronsky turned out to be a secret weapon. Within six months, Ricks had been promoted to run Lilly’s biomedicine unit and Skovronsky was working for him.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Cell therapy fails to slow type 1 diabetes, but safety is established

WSS

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

Health care needs a new profession: neuroimaging counseling

Obesity drug from Roche shows promise in early study

Bird flu outbreak in cows is latest avian flu curveball

WuXi Biologics beefs up its lobbying operation

Medical bills so high, Medicare adding extra digits to claim forms

leisure time

leisure time

Wikipedia

Medicare proposal to cover medical devices draws a mixed reaction

Fertility clinic egg and embryo storage is a disaster

Bright Health sells Medicare Advantage business to Molina

Close Medicare's dangerous gaps in addiction treatment coverage

DIEP, the 'gold standard' of breast reconstruction, is under threat

The White House hikes tariffs on plastic syringes made in China

Supreme Court strikes down use of affirmative action

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

As demand for Covid shots wanes, Moderna seeks its next success

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

entertainment

Q&A: Jennifer Adair on making gene therapy available globally

Bird flu outbreak in cows is latest avian flu curveball

Key Senate committee drafts bipartisan bill to stem drug shortages

WuXi Biologics execs register to lobby as Congress comes for the company

Melinda French Gates resigns from Gates Foundation

Cell therapy fails to slow type 1 diabetes, but safety is established

Wikipedia

knowledge

entertainment

focus